Efficacy and Safety of Crizotinib in Advanced or Recurrent ALK-positive Non-small Cell Lung Cancer
Conclusion Crizotinib can be used for the treatment of advanced NSCLC with ALK fusion/translocation. It is highly effective and well tolerated.
DOI: 10.3779/j.issn.1009-3419.2019.08.02
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | China Health | Fish | Genetics | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Pneumonia | Study | Translocation | Weight Loss